The College of Pharmacy at the University of Kentucky is recruiting in the area of Genetics/Genomics/Pharmacogenomics of Immune Function in Disease for a 12-month, tenure-track appointment at the Assistant Professor level with an anticipated start date of Fall 2020, although exceptional candidates at any level can also be considered. We seek candidates who can help grow our new program in the modulation of immune function as it impacts disease with expertise in relating genotype to phenotypic response, as well as in genetic approaches to the diagnosis and prediction of disease, or the discovery, development and evaluation of novel therapeutic interventions. Special consideration will be given to candidates whose research interests complement the College’s signature research themes including substance use disorders, cancer, neurological and metabolic disorders, and infectious diseases.
All candidates must possess a PharmD, PhD, PharmD/PhD, MD/PhD or other advanced degree(s) in pharmaceutical sciences or a related discipline and a record of scholarship and research productivity. Selected candidates will be expected to develop and maintain an extramurally-supported research program, engage in the College of Pharmacy graduate training program, and contribute significantly to providing the conceptual and practical skills for the next generation of professional Pharm.D. students to become leaders in the field of pharmacy practice.
St. Jude Children’s Research Hospital is seeking an innovative and strategic leader to serve as the Chair of the Department of Pharmaceutical Sciences. The successful candidate will have a strong track record of scholarship in pharmaceutical sciences as well as demonstrated leadership experience. Work experience in a cancer research setting is highly desirable as is the ability to effectively foster a supportive and collaborative workplace dedicated to cutting-edge research and optimal clinical care. Additional expectations include strong communications skills, financial acumen to oversee the departmental budget, ability to secure extramural funding and dedication to faculty mentorship and career development.
The Department of Pharmaceutical Sciences plays a central role in advancing the institutional mission of finding cures and saving children through research and treatment for pediatric cancer and other life-threatening diseases. The department has historically integrated both pharmaceutical sciences (with a primary mission of research), and pharmaceutical services (with a primary mission of clinical care), with a goal of rapidly translating research findings into clinical care. Its primary goals are to discover the biological basis for inter-individual differences in response to medications, to translate research findings to improve treatment outcomes, and to provide the best and most comprehensive pharmaceutical care for St. Jude patients. Department faculty are internationally recognized for their research in fundamental and clinical pharmacology, pharmacokinetics, pharmacodynamics, pharmacogenomics, pediatric therapeutics, and medication safety. The department includes Pharmaceutical Services, the CAP/CLIA-accredited Clinical Pharmacokinetics and Therapeutic Drug Monitoring Laboratory for St. Jude, as well as the Comprehensive Cancer Center’s Pharmacokinetics Shared Resource.
The department and institution provide a collaborative environment designed to foster transdisciplinary work in basic, translational and clinical sciences. The department hosts multiple regular multidisciplinary meetings and webinars, and its faculty, staff, and trainees are highly collaborative with other clinical, translational, and basic science research departments at St. Jude, as well as at the University of Tennessee Colleges of Medicine and Pharmacy. The department supports education and training of professional students, graduate students, clinical fellows, PGY2 pharmacy residents, and post-doctoral fellows. Pharmaceutical Sciences Department faculty, staff, and trainees work closely with each other; with collaborators in other departments at St. Jude; and with colleagues around the world to advance research and cures for pediatric patients. Additional details about the department can be found: https://www.stjude.org/research/departments-divisions/pharmaceutical-sciences.html
Applications and nominations should be sent to the Search Committee Chair via Melissa Jones at firstname.lastname@example.org.
The PGRN Hub congratulates the 2019 PGRN Poster Session at ASHG Trainee Award Winners.
Trainee Award Winners
Genetic basis of pharmacokinetic variability in African Americans
Tanima De, Northwestern University
Massively parallel functional profiling of CYP2C9 variants using a yeast activity assay
Clara Amorosi, University of Washington
A Pilot Clinical Trial of a CYP2D6 Genotype-Guided Pain Management Strategy in Patients Undergoing Total Joint Arthroplasty
Cameron D. Thomas, University of Florida
Pharmacogenomics of Docetaxel Response in Prostate Cancer: A Precision Medicine Initiative
Abhinav Grover, University of California, Irvine
Transcriptome-wide association study of anthracycline-induced cardiotoxicity in pediatric cancer patients
Erika N. Scott, University of British Columbia
HLA Haplotype DRB1*07:01-DQA1*02:01-DQB1*02:02 Predicts Pegaspargase Hypersensitivity
Yiwei Liu, St. Jude Children's Research Hospital
Quantitative proteomic profile of Caribbean Hispanics with high on-treatment platelet reactivity (HTPR) to clopidogrel
Ednalise Santiago, University of Puerto Rico - Medical Sciences Campus
The Department of Pharmaceutical Sciences and Experimental Therapeutics invites applications for a twelve-month, tenure track Assistant/Associate Professor with research interests in Pharmacogenomics, to join the Division of Pharmaceutics and Translational Therapeutics. The duties of this position include developing and/or maintaining an active research program in genomic science and methodology, including development of collaborations to integrate genomic/genetic/epigenetic science into practice-based and clinical research, as well as advancing knowledge in pharmacogenomic science. In addition to scholarly pursuits, the candidate will be expected to contribute to excellence in the teaching programs of the College of Pharmacy, in mentoring graduate students and post-doctoral scholars, and in providing service to the department, college, university and scientific community.
The Division of Pharmaceutics and Translational Therapeutics consists of faculty members with expertise in pharmacokinetics, pharmacodynamics, experimental therapeutics, biomaterials, pharmaceutics, pharmaceutical chemistry and drug delivery. The Division is home to two Ph.D. subtracks, one focused in Pharmaceutics and the other in the Clinical Pharmaceutical Sciences; more than 50 graduate students, post-doctoral fellows and visiting scientists participate in the educational and research programs within the division, and the College of Pharmacy enrolls over 400 students in the Pharm.D. professional degree program.
The PGRN Poster Session & Reception will be held on October 17th, 2019 during the 2019 ASHG Annual Meeting in Houston . Abstract poster submission deadline is August 31st, 2019 - authors will be notified of their submission's status by September 15th, 2019.
Leadership opportunity in functional genomics, pharmacogenomics, and personalized therapeutics at The Ohio State University College of Medicine
The College of Medicine at the Wexner Ohio State Medical Center plans significant expansion in genomics and personalized medicine. Building on an existing College of Medicine Center for Pharmacogenomics, a new leader will have the opportunity to build a substantial group of investigators covering all aspects of genetics and genomics, with a strong clinical translational component, exemplified in pharmacogenomics and personalized therapeutics. While cancer has been an area of strength at OSU, several new initiatives and recruitment strategies are ongoing in multiple medical disciplines, each in need of broad genomics expertise to integrate existing resources with new focused studies.
I here solicit informal requests or recommendations for any senior investigators, or advanced mid-level scientists, who want to explore this unique opportunity. Please address confidential inquiries or recommendations to:
Wolfgang Sadee, Dr.rer.nat.
Felts Mercer Professor of Medicine and Pharmacology
Vice Chair, Department of Cancer Biology and Genetics
Director, College of Medicine Center for Pharmacogenomics
1004 BRT, 460 W 12th Avenue
The Ohio State University
Columbus OH 43210
tel. 614-330 0509 (cell)
PGRN members are invited to participate in a survey about the future of the PGRN. The NIH (which is our only source of financial support), will no longer support the PGRN after June 2020. We are exploring options that will allow the PGRN to continue to exist as part of another organization, and would like to hear from our members which PGRN services and activities are most important. This survey should take no longer than 10 minutes to complete. We hope that you take the time to complete this important survey by Friday, May 17.
The ASHG abstract submission site for the 2019 ASHG Annual Meeting in Houston on October 15-19, 2019 is now open. There is an abstract topic of “Precision Medicine, Pharmacogenomics, and Genetic Therapies” that pharmacogenomics researchers may be interested in. The abstract submission deadline is June 6, 2019 at 8 pm Eastern time.
A team of researchers from the UK (University of Liverpool; University of St. Andrews; Cochrane Editorial Unit, London) are currently developing the “STrengthening the Reporting Of Pharmacogenetic Studies” (STROPS) reporting guideline in order to improve the reporting of pharmacogenetic studies, and to facilitate the conduct of high-quality systematic reviews and meta-analyses. They are conducting a Delphi survey to gain consensus opinion on which reporting items ought to be included in this guideline and are looking for participants to participate in a survey.
The Delphi survey will consist of two rounds of electronic-based survey, response and feedback. In the first round survey, participants will be asked to score reporting items based on their opinions about the importance of these items for inclusion in the reporting guideline. In the second round survey, a summary of responses from the first round will be provided, and participants will be asked to re-score the reporting items. Any additional reporting items identified by participants in the first round will be included for scoring by participants in the second round of the Delphi survey. Completion of the first round survey does not necessitate completion in the second round survey. All scoring data will be anonymized. This survey will take approximately 60-90 minutes to complete.
If you would like to participate in the development of this reporting guideline, please complete the first round of the Delphi survey by Friday, May 3 at the link below.
The Hub team